United States Biotechnology & Medical Research

Xenon Pharmaceuticals Inc (XENE)

Track

Over the last 90 days, Xenon Pharmaceuticals Inc. has seen a net sell-off of approximately $133,488 from insider transactions, with no insider buying reported. A total of seven transactions occurred, all of which were sales. The company's stock has performed strongly, up 19.8% in the past 90 days, and is near its 52-week high.
Ticker: XENE Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Xenon Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Patou, Gary
Director of Issuer
1 sale — total 70,251 USD
Sale 5 Jun 2026
Value US$1,811,847.37 | Price 448.99 | Shares 84,222
Sale 5 Jun 2026
Value US$4,083,882.01 | Price 382.63 | Shares 88,040
Planned sale 5 Jun 2026
Value US$70,251.08 | Price 53.14 | Shares 1,322
Planned sale 5 Jun 2026
Value US$63,236.60 | Price 53.14 | Shares 1,190
Proposed sale 5 Jun 2026
Value US$70,052.78 | Price 52.99 | Shares 1,322
Proposed sale 5 Jun 2026
Value US$70,052.78 | Price 52.99 | Shares 1,322
Proposed sale 5 Jun 2026
Value US$63,058.10 | Price 52.99 | Shares 1,190
Sale 13 Mar 2026
Value US$403,584.30 | Price 55.23 | Shares 7,308
Sale 13 Mar 2026
Value US$77,867.25 | Price 55.23 | Shares 1,410
Sale 13 Mar 2026
Value US$74,111.95 | Price 55.23 | Shares 1,342
Planned sale 13 Mar 2026
Value US$77,867.25 | Price 55.23 | Shares 1,410
Planned sale 13 Mar 2026
Value US$74,111.95 | Price 55.23 | Shares 1,342
Planned sale 13 Mar 2026
Value US$403,584.30 | Price 55.23 | Shares 7,308
Proposed sale 13 Mar 2026
Value US$77,867.00 | Price 55.22 | Shares 1,410
Proposed sale 13 Mar 2026
Value US$74,112.00 | Price 55.23 | Shares 1,342
Proposed sale 13 Mar 2026
Value US$403,583.00 | Price 55.22 | Shares 7,308
Sale 10 Mar 2026
Value US$156,701.56 | Price 60.11 | Shares 2,607
Planned sale 10 Mar 2026
Value US$156,701.56 | Price 60.11 | Shares 2,607
Planned sale 10 Mar 2026
Value US$166,559.27 | Price 60.11 | Shares 2,771
Planned sale 10 Mar 2026
Value US$677,357.05 | Price 60.11 | Shares 11,269
Proposed sale 10 Mar 2026
Value US$156,702.00 | Price 60.11 | Shares 2,607
Proposed sale 10 Mar 2026
Value US$677,357.00 | Price 60.11 | Shares 11,269
Proposed sale 10 Mar 2026
Value US$166,559.00 | Price 60.11 | Shares 2,771
Sale 9 Mar 2026
Value US$4,033,900.00 | Price 62.06 | Shares 65,000
Sale 9 Mar 2026
Value US$2,568,802.48 | Price 59.26 | Shares 43,348
Sale 9 Mar 2026
Value US$150,025.74 | Price 61.26 | Shares 2,449
Sale 9 Mar 2026
Value US$609,053.84 | Price 60.47 | Shares 10,072
Sale 9 Mar 2026
Value US$742,500.50 | Price 59.50 | Shares 12,479
Sale 9 Mar 2026
Value US$1,301,442.35 | Price 60.49 | Shares 21,515
Sale 9 Mar 2026
Value US$1,897,836.72 | Price 59.88 | Shares 31,694
Sale 9 Mar 2026
Value US$1,281,528.71 | Price 58.81 | Shares 21,791
Sale 9 Mar 2026
Value CA$3,704,052.16 | Price 60.08 | Shares 61,652
Planned sale 9 Mar 2026
Value US$4,033,900.00 | Price 62.06 | Shares 65,000
Planned sale 9 Mar 2026
Value US$3,704,052.16 | Price 60.08 | Shares 61,652
Planned sale 9 Mar 2026
Value US$2,568,802.48 | Price 59.26 | Shares 43,348
Planned sale 9 Mar 2026
Value US$150,025.74 | Price 61.26 | Shares 2,449
Planned sale 9 Mar 2026
Value US$609,053.84 | Price 60.47 | Shares 10,072
Planned sale 9 Mar 2026
Value US$742,500.50 | Price 59.50 | Shares 12,479
Planned sale 9 Mar 2026
Value US$1,301,442.35 | Price 60.49 | Shares 21,515
Planned sale 9 Mar 2026
Value US$1,897,836.72 | Price 59.88 | Shares 31,694
Planned sale 9 Mar 2026
Value US$1,281,528.71 | Price 58.81 | Shares 21,791
Proposed sale 9 Mar 2026
Value US$16,289,196.00 | Price 60.33 | Shares 270,000
Sale 2 Jan 2026
Value US$92,645.66 | Price 44.93 | Shares 2,062
Sale 2 Jan 2026
Value US$1,684,447.20 | Price 44.40 | Shares 37,938
Proposed sale 2 Jan 2026
Value US$1,777,166.23 | Price 44.43 | Shares 40,000
Planned sale 2 Jan 2026
Value US$92,645.66 | Price 44.93 | Shares 2,062
Planned sale 2 Jan 2026
Value US$1,684,447.20 | Price 44.40 | Shares 37,938
Sale 8 Dec 2025
Value CA$93,103.20 | Price 46.32 | Shares 2,010
Sale 8 Dec 2025
Value CA$402,103.80 | Price 45.59 | Shares 8,820
Planned sale 8 Dec 2025
Value US$93,103.20 | Price 46.32 | Shares 2,010
Planned sale 8 Dec 2025
Value US$402,103.80 | Price 45.59 | Shares 8,820
Proposed sale 8 Dec 2025
Value US$495,248.00 | Price 45.73 | Shares 10,830
Sale 5 Dec 2025
Value CA$647,306.25 | Price 45.03 | Shares 14,375
Planned sale 5 Dec 2025
Value US$647,306.25 | Price 45.03 | Shares 14,375
Proposed sale 5 Dec 2025
Value US$647,360.00 | Price 45.03 | Shares 14,375
Sale 28 Nov 2025
Value US$4,365.97 | Price 45.01 | Shares 97
Planned sale 28 Nov 2025
Value US$4,365.97 | Price 45.01 | Shares 97
Proposed sale 28 Nov 2025
Value US$4,366.00 | Price 45.01 | Shares 97
Sale 1 Oct 2025
Value US$1,004,000.00 | Price 40.16 | Shares 25,000
Proposed sale 1 Oct 2025
Value US$1,004,117.00 | Price 40.16 | Shares 25,000
Planned sale 1 Oct 2025
Value US$1,004,000.00 | Price 40.16 | Shares 25,000
Proposed sale 19 Sep 2025
Value US$94,490.00 | Price 37.08 | Shares 2,548
Sale 5 Jun 2025
Value US$91.44 | Price 30.48 | Shares 3
Sale 5 Jun 2025
Value US$91.44 | Price 30.48 | Shares 3
Sale 27 Jan 2025
Value US$47,189.43 | Price 41.07 | Shares 1,149
Sale 27 Jan 2025
Value US$613,616.36 | Price 40.46 | Shares 15,166
Proposed sale 27 Jan 2025
Value US$660,822.52 | Price 40.50 | Shares 16,315
Planned sale 27 Jan 2025
Value US$47,189.43 | Price 41.07 | Shares 1,149
Planned sale 27 Jan 2025
Value US$613,616.36 | Price 40.46 | Shares 15,166
Sale 24 Jan 2025
Value US$903,213.60 | Price 40.20 | Shares 22,468
Planned sale 24 Jan 2025
Value US$903,213.60 | Price 40.20 | Shares 22,468
Proposed sale 24 Jan 2025
Value US$903,299.07 | Price 40.20 | Shares 22,468
Sale 23 Jan 2025
Value US$649,977.36 | Price 40.08 | Shares 16,217
Planned sale 23 Jan 2025
Value US$649,977.36 | Price 40.08 | Shares 16,217
Proposed sale 23 Jan 2025
Value US$649,927.65 | Price 40.08 | Shares 16,217
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-09 2026-06-05 S Sale
2.2
Patou, Gary

Director of Issuer

Non-Executive Director
84,222 -45.5%
448.99
US$1,811,847 		84,222 -45.5% 448.99 US$1,811,847
2026-06-09 2026-06-05 S Sale
Cannon, Gillian

Director of Issuer

Non-Executive Director
88,040 +44.5%
382.63
US$4,083,882 		88,040 +44.5% 382.63 US$4,083,882
2026-06-08 2026-06-05 PlS Planned sale
2.1
PATOU GARY
Non-Executive Director
88,478 +20.8%
89.81
US$823,931 		88,478 +20.8% 89.81 US$823,931
2026-06-08 2026-06-05 PlS Planned sale
Cannon Gillian
Non-Executive Director
1,190 -45.0%
53.14
US$63,237 		1,190 -45.0% 53.14 US$63,237
2026-06-05 2026-06-05 PrS Proposed sale
2.1
GARY PATOU

Director

Non-Executive Director
1,322
52.99
US$70,053 		1,322 52.99 US$70,053
2026-06-05 2026-06-05 PrS Proposed sale
2.1
GARY PATOU

Director

Non-Executive Director
1,322
52.99
US$70,053 		1,322 52.99 US$70,053
2026-06-05 2026-06-05 PrS Proposed sale
GILLIAN CANNON

Director

Non-Executive Director
1,190
52.99
US$63,058 		1,190 52.99 US$63,058
2026-03-16 2026-03-13 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
7,308 -26.8%
55.23
US$403,584 		7,308 -26.8% 55.23 US$403,584
2026-03-16 2026-03-13 S Sale
1.8
Kenney, Christopher John

Senior Officer of Issuer

Officer
1,410 -16.6%
55.23
US$77,867 		1,410 -16.6% 55.23 US$77,867
2026-03-16 2026-03-13 S Sale
2.2
DiFabio, Andrea

Senior Officer of Issuer

Officer
1,342 -15.5%
55.23
US$74,112 		1,342 -15.5% 55.23 US$74,112
2026-03-13 2026-03-13 PlS Planned sale
2.2
KENNEY CHRISTOPHER JOHN

Chief Medical Officer

Officer
1,410 -16.6%
55.23
US$77,867 		1,410 -16.6% 55.23 US$77,867
2026-03-13 2026-03-13 PlS Planned sale
DiFabio Andrea

Chief Legal Officer

Officer
1,342 -15.5%
55.23
US$74,112 		1,342 -15.5% 55.23 US$74,112
2026-03-13 2026-03-13 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
7,308 -26.8%
55.23
US$403,584 		7,308 -26.8% 55.23 US$403,584
2026-03-13 2026-03-13 PrS Proposed sale
2.2
CHRISTOPHER JOHN KENNEY

Officer

Officer
1,410
55.22
US$77,867 		1,410 55.22 US$77,867
2026-03-13 2026-03-13 PrS Proposed sale
ANDREA DIFABIO

Officer

Officer
1,342
55.23
US$74,112 		1,342 55.23 US$74,112
2026-03-13 2026-03-13 PrS Proposed sale
2.9
IAN MORTIMER

Officer; Director

Executive Director
7,308
55.22
US$403,583 		7,308 55.22 US$403,583
2026-03-13 2026-03-10 S Sale
2.2
DiFabio, Andrea

Senior Officer of Issuer

Officer
2,607 -34.8%
60.11
US$156,702 		2,607 -34.8% 60.11 US$156,702
2026-03-11 2026-03-10 PlS Planned sale
DiFabio Andrea

Chief Legal Officer

Officer
2,607 -34.8%
60.11
US$156,702 		2,607 -34.8% 60.11 US$156,702
2026-03-11 2026-03-10 PlS Planned sale
2.2
KENNEY CHRISTOPHER JOHN

Chief Medical Officer

Officer
2,771 -36.9%
60.11
US$166,559 		2,771 -36.9% 60.11 US$166,559
2026-03-11 2026-03-10 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
11,269 -43.3%
60.11
US$677,357 		11,269 -43.3% 60.11 US$677,357
2026-03-10 2026-03-10 PrS Proposed sale
ANDREA DIFABIO

Officer

Officer
2,607
60.11
US$156,702 		2,607 60.11 US$156,702
2026-03-10 2026-03-10 PrS Proposed sale
2.9
IAN MORTIMER

Officer; Director

Executive Director
11,269
60.11
US$677,357 		11,269 60.11 US$677,357
2026-03-10 2026-03-10 PrS Proposed sale
2.2
CHRISTOPHER JOHN KENNEY

Officer

Officer
2,771
60.11
US$166,559 		2,771 60.11 US$166,559
2026-03-13 2026-03-09 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
65,000 -91.5%
62.06
US$4,033,900 		65,000 -91.5% 62.06 US$4,033,900
2026-03-13 2026-03-09 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
61,652 -91.1%
60.08
CA$3,704,052 		61,652 -91.1% 60.08 CA$3,704,052
2026-03-13 2026-03-09 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
43,348 -39.1%
59.26
US$2,568,802 		43,348 -39.1% 59.26 US$2,568,802
2026-03-13 2026-03-09 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
2,449 -29.0%
61.26
US$150,026 		2,449 -29.0% 61.26 US$150,026
2026-03-13 2026-03-09 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
10,072 -54.4%
60.47
US$609,054 		10,072 -54.4% 60.47 US$609,054
2026-03-13 2026-03-09 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
12,479 -40.3%
59.50
US$742,500 		12,479 -40.3% 59.50 US$742,500
2026-03-13 2026-03-09 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
21,515 -78.2%
60.49
US$1,301,442 		21,515 -78.2% 60.49 US$1,301,442
2026-03-13 2026-03-09 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
31,694 -53.5%
59.88
US$1,897,837 		31,694 -53.5% 59.88 US$1,897,837
2026-03-13 2026-03-09 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
21,791 -26.9%
58.81
US$1,281,529 		21,791 -26.9% 58.81 US$1,281,529
2026-03-11 2026-03-09 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
65,000 -91.5%
62.06
US$4,033,900 		65,000 -91.5% 62.06 US$4,033,900
2026-03-11 2026-03-09 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
61,652 -91.1%
60.08
US$3,704,052 		61,652 -91.1% 60.08 US$3,704,052
2026-03-11 2026-03-09 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
43,348 -37.4%
59.26
US$2,568,802 		43,348 -37.4% 59.26 US$2,568,802
2026-03-11 2026-03-09 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
2,449 -29.0%
61.26
US$150,026 		2,449 -29.0% 61.26 US$150,026
2026-03-11 2026-03-09 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
10,072 -54.4%
60.47
US$609,054 		10,072 -54.4% 60.47 US$609,054
2026-03-11 2026-03-09 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
12,479 -40.3%
59.50
US$742,500 		12,479 -40.3% 59.50 US$742,500
2026-03-11 2026-03-09 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
21,515 -78.2%
60.49
US$1,301,442 		21,515 -78.2% 60.49 US$1,301,442
2026-03-11 2026-03-09 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
31,694 -53.5%
59.88
US$1,897,837 		31,694 -53.5% 59.88 US$1,897,837
2026-03-11 2026-03-09 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
21,791 -26.9%
58.81
US$1,281,529 		21,791 -26.9% 58.81 US$1,281,529
2026-03-09 2026-03-09 PrS Proposed sale
2.9
IAN MORTIMER

Officer; Director

Executive Director
270,000
60.33
US$16,289,196 		270,000 60.33 US$16,289,196
2026-01-06 2026-01-02 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
2,062 -25.6%
44.93
US$92,646 		2,062 -25.6% 44.93 US$92,646
2026-01-06 2026-01-02 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
37,938 -82.5%
44.40
US$1,684,447 		37,938 -82.5% 44.40 US$1,684,447
2026-01-02 2026-01-02 PrS Proposed sale
2.9
IAN MORTIMER

Officer; Director

Executive Director
40,000
44.43
US$1,777,166 		40,000 44.43 US$1,777,166
2026-01-02 2026-01-02 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
2,062 -25.6%
44.93
US$92,646 		2,062 -25.6% 44.93 US$92,646
2026-01-02 2026-01-02 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
37,938 -82.5%
44.40
US$1,684,447 		37,938 -82.5% 44.40 US$1,684,447
2025-12-10 2025-12-08 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
2,010 -25.1%
46.32
CA$93,103 		2,010 -25.1% 46.32 CA$93,103
2025-12-10 2025-12-08 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
8,820 -52.4%
45.59
CA$402,104 		8,820 -52.4% 45.59 CA$402,104
2025-12-09 2025-12-08 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
2,010 -25.1%
46.32
US$93,103 		2,010 -25.1% 46.32 US$93,103
2025-12-09 2025-12-08 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
8,820 -52.4%
45.59
US$402,104 		8,820 -52.4% 45.59 US$402,104
2025-12-08 2025-12-08 PrS Proposed sale
2.9
IAN MORTIMER

Officer; Director

Executive Director
10,830
45.73
US$495,248 		10,830 45.73 US$495,248
2025-12-10 2025-12-05 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
14,375 -46.1%
45.03
CA$647,306 		14,375 -46.1% 45.03 CA$647,306
2025-12-09 2025-12-05 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
14,375 -46.1%
45.03
US$647,306 		14,375 -46.1% 45.03 US$647,306
2025-12-05 2025-12-05 PrS Proposed sale
2.9
IAN MORTIMER

Officer; Director

Executive Director
14,375
45.03
US$647,360 		14,375 45.03 US$647,360
2025-12-04 2025-11-28 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
97 -0.3%
45.01
US$4,366 		97 -0.3% 45.01 US$4,366
2025-12-03 2025-11-28 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
97 -0.3%
45.01
US$4,366 		97 -0.3% 45.01 US$4,366
2025-12-01 2025-11-28 PrS Proposed sale
2.9
IAN MORTIMER

Officer; Director

Executive Director
97
45.01
US$4,366 		97 45.01 US$4,366
2025-10-02 2025-10-01 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
25,000 -44.4%
40.16
US$1,004,000 		25,000 -44.4% 40.16 US$1,004,000
2025-10-01 2025-10-01 PrS Proposed sale
2.9
IAN MORTIMER

Officer; Director

Executive Director
25,000
40.16
US$1,004,117 		25,000 40.16 US$1,004,117
2025-10-01 2025-10-01 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT, CEO & INTERIM CFO

Executive Director
25,000 -44.4%
40.16
US$1,004,000 		25,000 -44.4% 40.16 US$1,004,000
2025-09-19 2025-09-19 PrS Proposed sale
3.5
SHERRY AULIN

Former officer

Officer
2,548
37.08
US$94,490 		2,548 37.08 US$94,490
2025-06-10 2025-06-05 S Sale
0.7
Gannon, Steven

Director of Issuer

Non-Executive Director
3 -0.1%
30.48
US$91 		3 -0.1% 30.48 US$91
2025-06-06 2025-06-05 S Sale
3.8
GANNON STEVEN
Non-Executive Director
3 -0.0%
30.48
US$91 		3 -0.0% 30.48 US$91
2025-01-28 2025-01-27 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
1,149 -3.5%
41.07
US$47,189 		1,149 -3.5% 41.07 US$47,189
2025-01-28 2025-01-27 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
15,166 -32.6%
40.46
US$613,616 		15,166 -32.6% 40.46 US$613,616
2025-01-27 2025-01-27 PrS Proposed sale
2.9
IAN MORTIMER

Officer; Director

Executive Director
16,315
40.50
US$660,823 		16,315 40.50 US$660,823
2025-01-27 2025-01-27 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
1,149 -3.5%
41.07
US$47,189 		1,149 -3.5% 41.07 US$47,189
2025-01-27 2025-01-27 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
15,166 -32.6%
40.46
US$613,616 		15,166 -32.6% 40.46 US$613,616
2025-01-28 2025-01-24 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
22,468 -41.8%
40.20
US$903,214 		22,468 -41.8% 40.20 US$903,214
2025-01-27 2025-01-24 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
22,468 -41.8%
40.20
US$903,214 		22,468 -41.8% 40.20 US$903,214
2025-01-24 2025-01-24 PrS Proposed sale
2.9
IAN MORTIMER

Officer; Director

Executive Director
22,468
40.20
US$903,299 		22,468 40.20 US$903,299
2025-01-28 2025-01-23 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
16,217 -34.1%
40.08
US$649,977 		16,217 -34.1% 40.08 US$649,977
2025-01-27 2025-01-23 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
16,217 -34.1%
40.08
US$649,977 		16,217 -34.1% 40.08 US$649,977
2025-01-23 2025-01-23 PrS Proposed sale
2.9
IAN MORTIMER

Officer; Director

Executive Director
16,217
40.08
US$649,928 		16,217 40.08 US$649,928
Explore more

More insider trading research around Xenon Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America